Undisclosed Lead Programs
Pulmonary, Cardiac, Neurological, and Autoimmune Diseases
Pre-clinicalActive
Key Facts
Indication
Pulmonary, Cardiac, Neurological, and Autoimmune Diseases
Phase
Pre-clinical
Status
Active
Company
About Gatehouse Bio
Gatehouse Bio is an early-stage biotech applying AI to small RNA (sRNA) biology to discover novel therapeutic targets and design precision oligonucleotide drugs. Its core asset is the Code-Breaker™ platform, which aims to decipher complex mRNA::sRNA interactions to develop biomarker-guided therapies. The company is currently in the pre-clinical development stage, seeking research collaborations, business development partners, and investors to advance its lead programs toward human clinical trials.
View full company profile